ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Clinical trials for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE explained in plain language.
Never miss a new study
Get alerted when new ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE trials appear
Sign up with your email to follow new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a smart immune cell with a kill switch beat tough lymphomas?
⭐️ CURE ⭐️ Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
New chemo cocktail aims to treat rare lymphoma without heart damage
Disease control Not yet recruitingThis phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The st…
Matched conditions: ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC